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Abstract.  The capability of the integrin VLA-3 to 
function as a receptor for collagen (Coil), laminin 
(Lm), and fibronectin (Fn) was addressed using both 
whole cell adhesion assays and Iigand affinity 
columns. Analysis of VLA-3-mediated cell adhesion 
was facilitated by the use of a  small cell lung carci- 
noma line (NCI-H69), which expresses VLA-3 but 
few other integrins.  While VLA-3 interaction with Fn 
was often low or undetectable in cells having both 
VLA-3 and VLA-5,  NCI-H69 cells readily attached to 
Fn in a VLA-3-dependent manner.  Both Arg-Gly-Asp 
(RGD) peptide inhibition  studies, and Fn fragment 
affinity columns suggested that VLA-3, like VLA-5, 
may bind to the RGD site in human Fn.  However, un- 
like Fn, both Coil and Lm supported VLA-3-mediated 
adhesion that was not inhibited by RGD peptide, and 
was totally unaffected by the presence of VLA-5. In 
addition,  VLA-3-mediated binding to Fn was low in 
the presence of Ca  ++, but was increased 6.6-fold with 
Mg++, and 30-fold in the presence of Mn  ++. In con- 
trast, binding to Coil was increased only 1.2-fold with 
Mg++, and  1.7-fold in Mn  ++, as compared to the level 
seen. with Ca++, Together,  these experiments indicate 
that VLA-3 can bind Coil, Lm, and Fn, and also 
show that (a) VLA-3 can recognize both RGD- 
dependent and RGD-independent ligands,  and (b) 
different VLA-3 ligands have distinctly dissimilar diva- 
lent cation sensitivities. 
M 
~.MB~.RS of the integrin  family of cell adhesion re- 
ceptors are of major importance in mediating cell 
attachment to extracellular  matrix proteins (2, 24, 
31,  46).  The  integrins  are membrane-spanning  heterodi- 
mers, which have been divided into three major subfamilies, 
each containing  a common/5 subunit associated with multi- 
ple ot subunits.  Adding further complexity to the organiza- 
tion of integrins,  at least three examples of a  subunits  as- 
sociating  with more than one/5 subunit have recently been 
described (6, 15, 28, 29, 34, 56). Currently, there are at least 
15 different integrin or/5 subunit combinations,  and consider- 
able effort has been directed towards elucidating  their func- 
tional characteristics.  Among the integrins  in the/51 subunit 
family  (VLA proteins),  VLA-5  and  VLA-4 interact  with 
fibronectin (Fn), L  VLA-6 binds to laminin (Lm), and VLA-1 
and  VLA-2  each recognize  both collagen  (Coil)  and Lm 
(24).  The  VLA-3  structure  is  especially versatile having 
been implicated as a receptor for Fn, Coil, and Lm (19, 57). 
VLA-3 was originally  described as an antigen  (140000, 
120000, and 30000 Mr) recognized by the mAb J143, and 
present on nearly all cultured cell lines except for lymphoid 
cells (14). On normal tissue,  expression was limited  to a 
few cell types, including  kidney glomeruli,  and the basal 
I. Abbreviations used in this  paper: Coil,  collagen;  Fn, fibronectin;  Lm, 
laminin;  VNR, vitronectin  receptor  (av/33). 
cells of epidermis and other epithelia  (3,  14, 39, 41). Sub- 
sequent biochemical characterization  of the ot and/5 subunits 
(150,000/110,000  Mr  nonreduced)  of  VLA-3  established 
that it is a heterodimer belonging to the VLA/integrin family 
(26,  53).  The eDNA sequence for ,3  from hamster (55), 
and partial  sequence from chicken  (32)  is highly  similar 
(,,090%) to the human ~3 sequence (Takada,  Y.,  E. Mur- 
phy, E Pil, C. Cben, M. H. Ginsberg,  M. E. Hemler, manu- 
script submitted for publication),  but it is not closely related 
to any other published integrin  ot subunit sequence,  though 
clearly resembling ~  subunits  in general. 
Evidence for VLA-3-mediated  matrix adhesion  functions 
was obtained when  cell  attachment  to  Coil  and  Fn  was 
blocked by a mAb that recognized an or/5 subunit complex 
(57) identical  to VLA-3 (54).  VLA-3 may also play a role 
in cell-cell adhesion,  since (a) VLA-3 expression has been 
noted around the periphery of epidermal skin cells (3, 41), 
(b) immunoelectron  microscopy has revealed VLA-3 at sites 
of intercellular  contact (35), and (c) an anti-VLA-3 antibody 
inhibited homotypic cell-cell adhesion of a keratinocyte cell 
line (3). Also, VLA-3 has recently been implicated  as being 
one of several integrin receptors for the bacterial protein in- 
vasin, which promotes bacterial penetration through  mam- 
malian  cell membranes (33). 
At present there is incomplete and sometimes conflicting 
evidence concerning possible ligands for VLA-3. VLA-3 was 
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to a Fn affinity column (at low salt concentrations), and (b) 
80%  blocking of HT1080  cell adhesion to Fn by an anti- 
VLA-3 mAb (57). However, subsequent studies showed only 
30% inhibition of HT1080 cell attachment (58), and variable 
0-65 % inhibition of attachment by keratinocyte cell lines 
(3).  In biochemical studies, purified VLA-3 was shown to 
bind to Fn-coated plastic (19). However,  the original isola- 
tion  of Fn  receptors  from  MG63  cells  (43),  and  from 
placenta (44) using Fn affinity columns, yielded exclusively 
VLA-5 (not VLA-3), despite the large amounts of VLA-3 
present in those sources (27, 53).  Other laboratories have 
also reported VLA-5 binding to immobilized Fn, but neither 
rat (42), chicken (32),  nor human (4, 32) VLA-3 was found 
to bind to Fn affinity columns. 
The putative interaction of VLA-3 with Coil has also been 
supported by conflicting and variable results. Whereas an 
early study showed that anti-VLA-3 mAbs blocked HT1080 
cell attachment to Coil types I and VI by nearly 100%  (57), 
later experiments reported either 50% inhibition (58), or no 
inhibition of cell adhesion (3) (also see Table I below). In 
similar fashion, human VLA-3 from HTI080 cells bound to 
immobilized Coil types I and VI (57), but VLA-3 from mela- 
noma cells did not bind (37), and in a radiolabeled receptor 
assay, VLA-3 binding to Coll I and IV was either absent or 
weak (19). 
Ample support for VLA-3 binding to Lm has been ob- 
tained in Lm affinity  column experiments (11, 18), and in ra- 
diolabeled receptor binding experiments (19). In particular, 
VLA-3 appears to attach to a globular domain at the end of 
the Lm long arm (19), perhaps near the carboxyl terminus 
of the Lm B1 subunit. However,  in assays involving whole 
cells, variable results were obtained. Anti-VLA-3 antibodies 
inhibited Lm attachment by 50-70%  for one cell line, but 
only  10-20%  for another (3),  and in general anti-VLA-3 
mAbs have been ineffective as inhibitors of cell attachment 
to Lm (11); Table I, below. 
Considering that the evidence for VLA-3 binding to vari- 
ous ligands is variable and often not observed, it is not sur- 
prising that little information is available regarding potential 
sites of attachment. For example, it had not been determined 
if VLA-3 attached to Fn at the RGD site, like VLA-5 (46), 
or near the GPEILDVPST site,  like VLA-4 (22, 59), or at 
a  different site. 
To more fully assess the functions of VLA-3, we have car- 
ried out both biological (whole cell) and biochemical (af- 
finity column) experiments addressing (a) the interaction of 
VLA-3, in the presence and absence of VLA-5, with Fn and 
Fn fragments, (b) the interaction of VLA-3 with Coll and 
Lm,  (c)  the inhibitory effects  of Arg-Gly-Asp peptide on 
VLA-3-binding functions, and (d) the relative effects of diva- 
lent cations on VLA-3-dependent functions. 
Materials and Methods 
Cell Lines and Reagents 
The small cell lung carcinoma line NCI-H69 was obtained from the Ameri- 
can Type Culture Collection (Rockville, MD), and the human melanoma 
line LOX from Dr. L. B. Chen (Dana-Farber Cancer Institute). All the cell 
lines listed in Table I were grown in RPMI 1640 medium supplemented with 
10%  fetal bovine serum. 
Collagens type I and IV, human plasma fibronectin, and chymotryptic 
fragments of fibronectin (i.e., the collagen-binding peptide Fn-45, the cell- 
binding fragment Fn-120,  and the heparin H-binding peptide Fn-40), as 
well as the hexapeptides GRGESP and GRGDSP, were all purchased from 
Telios  Pharmaceuticals (La  Julia,  CA).  I_aminin  from the  Engelbreth- 
Holm-Swarm murine tumor was a gift from H. Kleinman (National Institute 
of Dental Research, Bethesda, MD). Coupling of polypeptides to cyanogen 
bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, 
NJ) was carried out according to the manufacturer's instructions, and the 
amount of ligand incorporated to Scpharose beads was estimated by the 
difference in absorbance at 280 nm of the supernatant before and after 
coupling. 
mAbs and specific antisera used throughout this study are as follows: 
12F1  (anti-t~2), TS2/7  (anti-txz),  J143  (anti-c~3), B-5G10  (anti-c~4), A-1A5 
(anti-/31), and J-2A2 (control) were obtained as described previously (26, 
27).  Anti-VLA-2 mAb 5E8 (60)  was from by R.  Bankert (Roswell Park 
Memorial Institute, Buffalo, NY); anti-VLA-3 mAb PIB5 (54, 57), and anti- 
VLA-5 mAb P1D6 (58) were from E. Wayner (University of Washington, 
Seattle, WA); GoH3, a mAb against VLA c~  6 (49) was from A. Sonnenberg 
(Netherlands Cancer Institute, Amsterdam, Holland); and rat mAb B1Ell 
(anti-/30 was from C.  Damsky (University of California San Francisco, 
San Francisco, CA). A rabbit antiserum to the COOH-terminal cytoplasmic 
tail of VLA c~  5 was a gift from S. Argraves (American Red Cross, Rock- 
ville, MD). The anti-t~  v mAb LM142 (5) was from D.  Cheresh (Scripps 
Clinic,  La Jolla,  CA),  and the anti-a  v mAbs  13C2  and 23C6  (7) were 
from M. Horton (Imperial Cancer Research Fund, London, England). An 
anti-/S3 mAb, called mAbl5 (16),  was from M. Ginsberg (Scripps Clinic, 
La Julia, CA), and rabbit antiserum to the COOH-terminai cytoplasmic tail 
of/35 was generated as previously described (45). 
Flow Cytometry 
Ceils (NCI-H69 and LOX) were washed with PBS containing 1% BSA and 
2 % human serum (HS; C,-ibco  Laboratories, Grand Island, NY), and prein- 
cubated in the same buffer (PBS/BSA/HS) for 30 rain at 4°C. Next, 2-3 
×  105 cells aliquots were treated individually with saturating concentra- 
tions of mAbs specific for VLA cx (txl-~x  6) and VLA/~ subunits (see previ- 
ous paragraph) in PBS/BSA/HS for 45 min at 4°C. Cells were washed three 
times with PBS/BSA/HS, subsequently incubated with goat anti-mouse IgG 
coupled to fluorescein (Cappel Laboratories, Malvern, PA; at a  1:30 dilu- 
tion of stock) for 45 rain at 4*C, washed three times as above, and finally 
resuspended in  PBS/BSA/HS.  Fluorescein-labeled cells  were  analyzed 
using a FACScan apparatus (a registered trademark of Becton Dickinson & 
Co., Oxnard, CA). 
Cell Attachment and mAb Inhibition Assays 
To assess cell attachment to extracellular matrix proteins, 5  ×  106 cells 
were incubated with SlCr (0.5  ~tCi;  1 Ci  =  37  GBq) for 4-6 h at 37°C, 
washed sequentially with PBS, followed  by 1 mM EDTA in PBS, and finally 
serum-free RPMI 1640  supplemented with 1% BSA (RPMI/BSA). Then 
cells were resnspended in RPMI/BSA and plated in triplicate (5  x  104 
cells/well) for 20-30 rain at 37°C on 96-well microtiter dishes (0.6 cm di- 
ameter per well) that had been previously incubated with Coil type I, Lm, 
or Fn (1/~g/well). After unbound cells were aspirated and the plates were 
washed three times with RPMI/BSA, 51Cr present in 0.1% SDS cell lysates 
was measured using a gamma counter. 
For inhibition experiments, dilutions of inhibitory mAb 0-5 t~g/well) 
were added to ligand-coated microtiter plates before addition of labeled 
cells, and adhesion assays were conducted exactly as described above. 
To analyze divalent cation sensitivity of VLA-3-mediated adhesion, cells 
were first washed with 1 mM EDTA in PBS to deplete extracellular levels 
of preexisting divalent metals. Subsequently, cells were equilibrated sep- 
arately with 1 mM each of either CaCI2, MgC12, or MnCl2 in 20 mM Tris, 
pH 7.4,  135 mM NaCl, 5 mM KCI, 2 mM glutamine, 1.8 mM glucose, and 
1% BSA, and plated on ligand-coated dishes to carry out adhesion assays 
as indicated above. 
Specific attachment of cells to extracellular matrix proteins was the aver- 
age of at least three separate experiments, and was expressed as cells bound 
per mm  2 (area of microtiter plate: 28 mm2/well) +  SD. Background bind- 
ing of radiolabeled cells to BSA-coated control wells was typically <0.5% 
of total input counts (or <10 cells/mm  2) and was subtracted during calcula- 
tion of specific attachment. 
AJSnity Chromatography of Cell Extracts on 
Immobilized Ligand Columns 
LOX melanoma cells were freshly detached from tissue culture plastic 
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teins (1-2  x  107 cells) were iodinated with 1/tCi of Na125I (Dupont-NEN 
Products,  Wilmington,  DE)  and  0.2  mg/ml of lactoperoxidase  (Sigma 
Chemical Co.,  St.  Louis, MO).  125I-labeled  cells were  solubilized with 
100 mM octylglucoside (Sigma Chemical Co.) and 100 mM octylthiogluco- 
side (Calbiochem-Behring Corp.,  San Diego, CA) in a  buffer containing 
PBS  supplemented with  0.1  mM  MnCt2,  I0  ~tg/ml  aprotinin,  10  /zM 
leupeptin, and 1 mM PMSF (buffer A) for 4 h at 4°C. All subsequent proce- 
dures were carded out at 0-4°C. Detergent extracts were clarified by cen- 
trifugation at 10,000 rpm, supplemented with 0.5 mg/ml BSA as a carrier 
protein, and loaded onto ligand-Sepharose columns (2 ml of packed gel with 
1-5 mg of ligand proteirdml of beads) equilibrated with 25 mM octylgluco- 
side and 25 mM octylthioglucoside in buffer A (buffer B). After the iodi- 
hated cell extract was allowed to interact with the immobilized ligand for 
a minimum of 4 h, the column was washed extensively with buffer B until 
the radioactivity of the eluate decreased to background levels (•20  column 
volumes). Subsequently, stepwise elution was carried out first with buffer 
B supplemented with 0.5 M NaC! (20 column volumes), followed by 10 mM 
EDTA in buffer B (10 column volumes), and finally 4 M  urea in buffer B 
(10 column volumes). Alternatively, ligand-Sepharose columns were eluted 
with  2  column volumes each  of  1  mM  GRGESP  followed  by  1  mM 
GRGDSP, both dissolved in buffer B. The affinity supports could be reused 
a  few times after immediate reequilibration in buffer B.  Eluted fractions 
were collected (0.8 mi each), and corresponding aliquots were analyzed for 
radioactivity  using  a  gamma counter  (Packard  Instrument  Co.,  Inc., 
Downers Grove, IL). 
Immunoprecipitation with Specific mAbs and Antisera 
Selected fractions from the affinity chromatography separations were im- 
manoprecipitated as previously described (26). Briefly, aliquots containing 
the same amount of radioactivity (cpm) were taken from column fractions 
and incubated with control mAb (J-2A2) and Staphylococcus aureus Cowan 
1 strain (Calbiochem-Behring Corp.) for 2 h at 4"C. After centrifugation 
of the nonspecifically bound immune complexes, the resulting supernatant 
was incubated with either 1 ttg of specific mAb or, alternatively, 5  /.d of 
specific antisera, followed by addition of a 10% suspension  ofS. aureus Co- 
wan 1 (50/zl) for 2 h at 4°C. Adsorbed immune  complexes were then washed 
four times with  PBS  containing 0.5%  NP-40,  0.5%  deoxycholate,  and 
0.02% azide, and subsequently suspended in SDS-PAGE sample buffer sup- 
plemented with or  without 5 %  2-mereaptoethanol.  After separation of 
polypeptides by SDS-PAGE (5 % polyacrylamide), gels were dried and iodi- 
hated protein bands were detected by exposing the gels to x-ray sensitive 
film (Kodak)  for up to 4  wk.  Molecular mass standards were:  myosin 
(200 kD),  beta-galactosidase (116 kD),  phosphorylase b  (92.5 kD),  and 
BSA (67 kD). 
Immunofluorescent Staining 
Cells growing on Fn- or Coil-type I-coated coverslips (for 4-6 h) were fixed 
with 3.7%  paraformaldehyde for 20 rain, permeabilized with 0.5% NP-40 
for 10 min, and stained with either the anti-VLA-3 mAb J143 (14),  or the 
anti-VLA ~ mAb A-1A5 (25), or polyclonal antibody to the COOH-terminal 
intracytoplasmic tail of VLA a 5. Since none of these antibodies are known 
to block integrin binding to extracellular matrix ligands, they were judged 
to be suitable for staining receptors involved in focal contacts. Rhodamine- 
conjugated goat anti-mouse or goat anti-rabbit IgG was used as secondary 
antibody (1:200-1:300 dilution of stock). Representative fields of cells were 
photographed through a Planapo 63 x  oil immersion lens on a  Zeiss Ax- 
iophot microscope equipped for epifluorescence. Some cells were also pho- 
tographed using differential interference contrast microscopy to compare 
the distribution of ceils to that of immunofluorescent staining. 
Results 
VLA-3-mediated Matrix Adhesion Is Not Apparent on 
Most Adherent Cell Lines 
To assess  the functional role of VLA-3, the best available 
anti-VLA-3 blocking reagent (mAb P1BS) was tested for inhi- 
bition of cell adhesion to Coil, Fn, and Lm. Typical results, 
shown in Table I, indicated that for most cell lines analyzed, 
the anti-VLA-3 mAb P1B5 had little or no inhibitory effect 
on cell attachment to Coil, Fn, or Lm. In contrast, cell ad- 
herence was almost completely abrogated by an anti-VLA 
~1  subunit  mAb  (B1Ell)  for  all  matrix  proteins  tested. 
Thus, while/~1 integrins were clearly involved in binding to 
Coil, Fn, and Lm, VLA-3-mediated matrix adhesion, if any, 
may have been overshadowed by the contribution of other 
VLA receptors. 
To simplify analysis of VLA-3 function, a VLA-3-positive 
cell line was sought which expressed few other VLA pro- 
teins. As shown in Fig.  1 A, the small cell lung carcinoma 
line NCI-H69 expressed a very unusual VLA protein pheno- 
type consisting of a moderate amount of VLA-3 and VLA-6, 
but no VLA-1,  VLA-2, VLA-4, or VLA-5. Also, there was 
no detectable o~  v (assessed using three different antibodies), 
B3, or B5 on NCI-H69 cells (not shown).  Thus,  in the ab- 
Table I. Anti-VLA-3 Antibody Inhibition of Cell Attachment to Matrix Ligands 
Collagen type I  Fibronectin  Laminin 
Cell line  Cell type  PIB5  B1Ell  P1B5  B1Ell  P1B5  BIEll 
76N  Normal breast  120  +  11  2  +  0.2  99  +  10  16  +  1.5  -  - 
epithelial 
CCLo228  Colon  110  +  8  1  +  0.1  97  +  8  12  ±  1  107  ±  10  5  ±  0.5 
carcinoma 
EJ  Bladder  107  +  10  7  ±  0.5  96  +  5  5  ±  0.3  103  +  10  1  ±  0.1 
carcinoma 
J82  Bladder  122  5:12  2  +  0.2  108  ±  9  5  +  0.4  106  ±  9  6  +  0.5 
carcinoma 
LOX  Melanoma  97  ±  5  5  ±  0.5  105  +  6  4  ±  0.3  95  +  6  3  +  0.2 
MRC-5  Normal  104  ±  7  4  ±  0.4  103  ±  9  10  ±  0.9  -  - 
fibroblast 
RD  Rhabdomyosarcoma  -  -  97  ±  8  5  ±  0.4  95  ±  7  1  +  0.1 
SK-N-SH  Neuroblastoma  98  ±  6  4  ±  0.2  99  +  10  9  ±  0.6  102  +  10  2  ±  0.2 
ZR-T  Breast epithelial  102  +  10  2  +  0.2  115  +  9  26  ±  2  114  +  10  1  +  0.1 
tumor 
HT1080  Fibrosarcoma  112  ±  10  3  +  0.2  98  ±  6  5  ±  0.4  97  ±  8  3  +  0.2 
The numbers shown represent cell attachment as a percentage of that observed in the presence of the control mAb J-2A2. Other mAb used are P1B5 (anti-VLA-3) 
and B1EI ! (anti-VLA/30. Attachment assays were carded out as described in Materials and Methods, and (-) indicates not done. The level of uninhibited bind- 
ing ranged from 500 to 1,500 cells/ram  2 for the various cell  lines, and background adhesion to BSA-coated controls was typically <10 cells/ram  2. 
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Figure 1. Cell surface expression of VLA proteins. Flow cytometry 
analysis was  performed  on small cell lung carcinoma cells NCI- 
H69 (A), and LOX melanoma cells (B). Saturating concentrations 
of the following mAbs were used for staining (see Materials and 
Methods): J-2A2 (control), TS2/7 (anti-VLA-l), 5E8 (anti-VLA-2), 
J143  (anti-VLA-3), B-5G10 (anti-VLA-4),  P1D6 (anti-VLA-5), 
GoH3 (anti-VLA-6), and A-1A5 (anti-VLA/~). 
sence of alternative Coil receptors (VLA-1 and VLA-2), al- 
ternative Fn receptors (VLA-4,  VLA-5,  ctvfl~, avfl3, ctVfls) 
and  alternative Lm receptors (VLA-1  and VLA-2),  it ap- 
peared that analysis of VLA-3 functions on NCI-H69 cells 
would be relatively uncomplicated. 
In contrast, the melanoma cell line LOX expressed a VLA 
protein phenotype that is  representative of many adherent 
cell lines (Fig.  1 B). The VLA-3, VLA-5, and VLA-6 pro- 
teins were expressed at comparably high levels, and VLA-2 
was present at a moderate level, whereas VLA-1 (not shown) 
and VLA-4 were present in lower amounts. 
VLA-3 and NCI-H69 Cells Mediates Adhesion to 
Matrix Proteins 
To optimize adherence of NCI-H69 cells to Coil, Lm, and 
Fn, the effect of  different divalent cations was tested (Fig. 2). 
While NCI-H69 cells bound efficiently to Lm and Fn, adhe- 
sion to Coil was weaker but statistically significant (Fig. 2). 
Attachment to matrix proteins of NCI-H69 cells, which had 
been previously depleted of preexisting cations (see Mate- 
rials and  Methods),  was best  supported by  1 mM  Mn++, 
followed by 1 mM Mg  ++, and then 1 mM Ca  ++. Titration of 
three different divalent cations over a  10-fold range revealed 
that maximal attachment of NCI-H69 cells to matrix pro- 
teins was achieved in the range of 0.5-1.0 mM for each cation 
(results not shown). 
To then determine which  integrins  might be mediating 
NCI-H69  cell  adhesion to the various  ligands,  inhibition 
studies were carried out. Attachment of NCI-H69 cells to Fn 
(Fig. 3 A), Lm (Fig. 3 B), and Coil (Fig. 3 C) was inhibited 
by the anti-VLA-3 mAb P1B5 by nearly 70, 40,  and 66%, 
respectively.  The  anti-VLA-6  mAb  GoH3  also  inhibited 
binding to Lm (by 53%), but did not inhibit adhesion to Coil 
Figure 2. Effect of divalent cations on adhesion of NCI-H69 cells 
to matrix proteins. NCI-H69 cells were washed with 1 mM EDTA 
in PBS to remove preexisting cations.  Cells  were subsequently 
equilibrated with buffers containing 1 mM each of either CaCl2, 
or MgC12, or MnCl2 and attachment of NCI-H69 cells to plastic 
plates coated with either Coil,  Lm,  or Fn was determined (see 
Materials and Methods). In control experiments, binding to BSA- 
coated plastic was <10 ceUs/mm  2. 
or to Fn. Control antibodies, including anti-VLA-2 and anti- 
VLA-5 did not inhibit (not shown), consistent with the ab- 
sence of those receptors from NCI-H69 cells. Anti-VLA fl~ 
subunit mAb B1Ell inhibited attachment to all three ligands 
by 90-100%,  indicating  that  NCI-H69  cell adhesion was 
largely due to/~1 integrins. As mentioned above, other inte- 
grin subunits such as o~  v,/33, and/3~,  which may contribute 
to fibronectin adhesion on some cells, were undetectable on 
NCI-H69 cells. 
The same mAb reagents used for Fig.  3, A-C were also 
tested for inhibitory effects on the melanoma cell line LOX 
(Fig. 3, D-F). The mAb P1B5 (anti-VLA-3) did not inhibit 
adhesion to any of the ligands tested (as also indicated in Ta- 
ble I). Instead, Fn attachment was blocked nearly 85 % by 
anti-VLA-5 (Fig. 3 D), Lm binding was diminished 56% by 
anti-VLA-2 and 77% by anti-VLA-6 (Fig. 3 E), and Coil at- 
tachment was reduced 76% by anti-VLA-2 (Fig. 3 F). In ad- 
dition, anti-/~l inhibition was 95 % or greater for all ligands, 
thus indicating that LOX cell adhesion was mostly due to 
fl~ integrins. These results suggest that for LOX cells, VLA 
proteins other than VLA-3 are the major receptors for Fn, 
Lm, and Coll. 
Differential Effects of  RGD on VLA-3-mediated 
Adhesion to Matrix Proteins 
To determine whether cell adhesion mediated by VLA-3 is 
RGD-dependent, peptide inhibition studies were conducted. 
Attachment of NCI-H69 cells to Fn (Fig. 3 A) was inhibited 
51% by the peptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) in 
this  experiment,  and  60-70%  in  other  experiments  (not 
shown).  In contrast, the control peptide Gly-Arg-Gly-Glu- 
Ser-Pro (GRGESP) had no effect on NCI-H69 cell adhesion 
(Fig. 3 A). Because VLA-3 appears to be the major integrin 
responsible for Fn binding, the GRGDSP peptide is probably 
The Journal of Cell Biology, Volume  112, 1991  172 Figure 3. Inhibition of cell attachment to matrix proteins.  Adhesion of NCI-H69 cells to microtiter plates coated with a 5 #g/well of Fn 
(A), Lm (B), or Coil type I (C) was tested in the presence of inhibitors. In a parallel experiment, adhesion of LOX cells to plastic plates 
coated with 1 #g/well of Fn (D), Lm (E), or Coil type I (F) was analyzed. The following mAbs were tested for inhibition of cell binding 
(concentration:  1-5/~g/well): J-2A2 (control), 5E8 (anti-VLA-2), PIB5 (anti-VLA-3), P1D6 (anti-VLA-5), GoH3 (anti-VLA-6), and B1Ell 
(anti-VLA/3).  The peptides GRGESP and GRGDSP were present at 0.2 mg/ml. 
inhibiting  VLA-3  in  these experiments.  Whereas  titration 
with GRGDSP peptide reached a plateau of 60-70 % inhibi- 
tion and titration with anti-VLA-3 rnAb reached a plateau of 
70-75 % inhibition (results not shown), a combination of the 
GRGDSP peptide and anti-VLA-3 mAb gave more inhibi- 
tion  (84%)  of Fn binding than either reagent added alone 
(Fig.  3 A). 
Consistent with the suggestion that VLA-3 may mediate 
attachment to the RGD site in Fn, NCI-H69 ceils bound well 
to the Fn-120 fragment of Fn, but not to other Fn fragments 
that do not contain the RGD sequence (not shown). 
Contrary to Fn, NCI-H69 cell attachment to Coil and Lm 
was not  inhibited  by the  GRGDSP peptide.  Furthermore, 
when GRGDSP peptide was added together with the anti- 
VLA-3 mAb, it did not increase the level of inhibition (Fig. 
3, B and C). However, a combination of anti VLA-3 and anti- 
VLA-6  antibodies  inhibited  Lm  attachment  by  67%,  an 
effect greater than either alone. In contrast, anti-VLA-6 plus 
anti-VLA-3 rnAbs did not increase inhibition of binding to 
Coil (or Fn) beyond that seen for anti-VLA-3 alone.  Taken 
together,  the  results  suggest that  VLA-3  may bind  to  the 
RGD site on FN, but may use a different recognition site for 
Coil and Lm. 
Differential  Effects of Divalent Cations on 
VLA-3-dependent Adhesion Functions 
The experiments shown in  Fig.  3  were carried out in the 
presence of 1 mM Mn  ++, to optimize NCI-H69 cell attach- 
ment. To further assess the specific effects of divalent cations 
on VLA-3 functions,  cell adhesion assays were performed 
using different divalent cations, after depletion of preexisting 
cations with EDTA (see Materials and Methods). As shown 
in Fig. 4, attachment of NCI-H69 cells could be (a) three- 
to  fourfold greater on  Fn  than  on  Coil  (when  Mn  ÷+ was 
present),  (b)  about the  same on both Fn  and  Coil  (when 
Mg  ++ was present), or (c) substantially less on Fn than on 
Coll (in the presence of Ca++). Stated another way,  adhe- 
sion to Coil was relatively unchanged whether Ca++, Mg  ++, 
or Mn  ++ was present,  whereas attachment to Fn  was ele- 
vated with Mn  ++, moderate with Mg  ++, and almost absent 
with  Ca  +÷.  Adhesion  to  Lm  (not  shown)  was  also  influ- 
enced by divalent cations.  However, because both VLA-6 
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Figure 4. Effect of divalent cations on NCI-H69 cell adhesion. Mi- 
crotiter plates were coated with increasing concentrations of  Fn and 
Coil type I, and attachment of NCI-H69 cells was examined in the 
presence  of 1 mM concentrations  of either  MnCI2, MgC12, or 
CaCI2 after NCI-H69 cells were previously depleted of preexisting 
cations by washing with  1 mM EDTA in PBS (see legend to Fig. 
2 and Materials  and Methods). 
and VLA-3 mediate NCI-H69 attachment to Lm (see Fig. 3 
B  above), these cation effects could not be specifically as- 
signed to VLA-3,  especially since VLA-6 is known to be 
highly influenced by divalent cations (50). 
VLA-3 Interacts with the Cell Binding Region of  Fn 
To further analyze the potential role of VLA-3 as a Fn recep- 
tor, affinity chromatography on Fn columns was carried out. 
The human melanoma cell line LOX, which expresses abun- 
dant levels of both VLA-3 and VLA-5 (see Fig.  1 B),  was 
subjected to cell surface iodination, and membrane proteins 
were  solubilized  with  octylglucoside  in  the  presence  of 
MnClv  Passage  of LOX  cell  extracts  over a  Fn  affinity 
column resulted in complete depletion of VLA-5 from the 
flowthrough  (unbound)  fraction  (Fig.  5,  lane  c),  whereas 
substantial levels of VLA-2 and VLA-3 passed through the 
column without binding (Fig. 5, lanes a and b). Upon incu- 
bation with 0.5 M  NaC1, small amounts of VLA-3 (Fig. 5, 
lane f) and VLA-5 (lane g), but not VLA-2 (lane e), were 
eluted from the Fn column. The bulk of VLA-5-reactive ma- 
terial was specifically eluted from the Fn column by subse- 
quent elution with EDTA (Fig. 5, lane k), while no additional 
VLA-3 was apparent in this fraction (lane j). Thus, VLA-3 
appeared to bind less completely than VLA-5 to immobi- 
lized Fn, and was selectively eluted using conditions that did 
not remove much VLA-5, i.e., high ionic strength. 
Incubation of the Fn column with EDTA (without previous 
addition of NaC1) resulted in complete elution of VLA-5, but 
only eluted a small fraction of VLA-3 (not shown). VLA-5 
Figure 5. Affinity chromatog- 
raphy  of LOX  cells  on  Fn- 
Sepharose. Octylglucoside ex- 
tracts  of LOX cells  contain- 
ing  MnCl2 were  fractionated 
on a  column  of immobilized 
Fn (see Mat.riMs  and Meth- 
ods). Aliquots of column elu- 
ates were subjected to immu- 
noprecipitation  with  mAbs, 
followed by SDS-PAGE anal- 
ysis.  The mAbs were:  12F1 
(lanes a, e, and i), J143 (lanes 
b,f, and j), P1D6 (lanes c, g, 
and k), and A-1A5 (lanes d, h, 
and 1). 
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kD  fragment  of  Fn.  (A)  Af- 
finity  chromatography  of  LOX 
cell extracts on either Fn-, or Fn- 
120-Sepharose. (B) Fractionation 
of VLA  5-depleted  extracts  of 
LOX cells on Fn 120-Sepharose. 
Immunoprecipitations were car- 
ried out with mAbs as indicated in 
the legend to Fig. 5. 
could also be specifically eluted from the Fn column with 
GRGDSP peptide, in agreement with previously published 
results (43). In contrast, attempts to elute VLA-3 using the 
GRGDSP peptide in this experiment were inconclusive (not 
shown). 
To localize the VLA-3 binding site on human plasma Fn, 
binding of LOX cell extracts to intact Fn and to the 120-kD 
chymotryptic fragment of Fn (which includes the RGD cell 
attachment sequence) was compared. Fig. 6 A shows the rel- 
ative amounts of VLA-3 from LOX cells that were unbound, 
or bound and subsequently eluted with EDTA. VLA-3 bound 
partially to both intact Fn (Fig. 6 A, compare lanes a  and 
b) and to the 120-kD fragment (compare lanes d and e), with 
a little less binding to the 120-kD fragment (compare lanes 
b  and e). In contrast, VLA-5 bound quantitatively to both 
intact and 120-kD fragment of Fn (Fig. 6 A, lanes c and f). 
Note that  100%  of the VLA-3 but only  10%  of the total 
VLA-5 yield is shown.  In a control experiment, there was 
no binding of either VLA-3, or VLA-5 to the 40-kD Hep II 
fragment of Fn,  which contains the sequence EILDVPST 
(not shown). In summary, although VLA-3 binding was sub- 
stantially weaker, both VLA-3 and VLA-5 appeared to inter- 
act with the  120-kD cell binding fragment of Fn. 
VLA-3 Binding to Fn Is RGD Dependent 
Affinity chromatography of LOX cells over Fn-Sepharose 
resulted in quantitative depletion of VLA-5 from the extract, 
while  substantial  amounts of VLA-3  remained in  the un- 
bound fraction (Fig. 5, lanes b and c). To assess the binding 
capacity of the remaining VLA-3 protein, a second fraction- 
ation step was carded out on a  Fn-120-Sepharose column 
using a VLA-5-depleted LOX cell extract (Fig. 6 B). In the 
absence of VLA-5, VLA-3 bound specifically to the Fn-120 
column, since most VLA-3, but not VLA-2, was conspicu- 
ously absent from the flowthrough (Fig. 6 B, g and h). Elu- 
tion of  VLA-3 from the Fn-120 column could then be accom- 
plished  by  treatment  with  EDTA  (Fig.  6  B,  lane  /).  As 
expected, VLA-5 could not be detected in either unbound or 
bound fractions (Fig.  6 B, lanes i and m).  The amount of 
VLA-3 in the EDTA eluate (lane/) was approximately equal 
to the total VLA protein that could be immunoprecipitated 
(lane n), thus suggesting that VLA-3 was the only VLA het- 
erodimer in this fraction. 
To evaluate the putative role of RGD and VLA-3 binding 
to Fn (or to its 120-kD fragment), VLA-5-depleted extracts 
of LOX cells were fractionated on Fn-Sepharose (Fig.  7). 
Consistent  with  the  results  described  above,  VLA-3  re- 
mained bound to the affinity column and was not eluted by 
washing with the control peptide GRGESP (Fig. 7, lane h). 
However, VLA-3 was readily eluted upon incubation with 
GRGDP (Fig. 7, lane m). In a  separate experiment, RGD- 
dependent elution of VLA-3 from Fn columns was also ob- 
tained  using  extracts  from  the  cell  line  NCI-H69  (not 
shown), which expresses VLA-3, but not VLA-5 (see Fig.  1 
A). Therefore, for at least two different cell lines VLA-3 may 
interact with the RGD site in Fn. This interaction was best 
observed when VLA-5 was first depleted (e.g., as from LOX 
cells), or was entirely absent (e.g., as from NCI-H69 cells). 
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affinity columns with RGD pep- 
tides.  LOX  cell  extracts  were 
depleted of VLA-5 by prior pas- 
sage through Fn-Sepharose, and 
subsequently rechromatographed 
on a column of immobilized Fn- 
120. The affinity support was sub- 
jected to stepwise elution with 1 
mg/ml  each  of  GRGESP,  fol- 
lowed by GRGDSP. 
VLA-3 Binding to CoU and Lm Is RGD-independent 
To examine the possibility that the RGD sequence may also 
be  required  for the  interaction of VLA-3  with  Coil  and 
Lm, affinity chromatography separations were carried out. 
VLA-3 bound to columns of immobilized Coil type I (Fig. 
8 A), Lm (Fig. 8 B), and Coil type IV (not shown). In each 
case partial elution was obtained with 0.5 M NaC1 (Fig. 8, 
lanes c and l), and complete elution with EDTA (lanes h and 
q). However, no elution of VLA-3 was obtained using RGD 
peptide (not shown). VLA-2 also bound to the Coil I (Fig. 
8 A, lane g) and Lm (not shown) columns, but unlike VLA-3, 
this integrin was not eluted with 0.5 M NaCI. Only a trace 
of VLA-6 was eluted from the Lm column with EDTA (Fig. 
8 B, lane s), and no binding of  VLA-5 was observed for either 
the Coil or Lm columns (Fig. 8, lanes d, i, m, and r). In con- 
clusion, VLA-3 binding to Coil and Lm, unlike that to Fn, 
appears to be largely RGD independent. 
Localization of VLA-3 and Other Integrins in 
Attached Cells 
To compare  the cell surface distribution of  VLA-3 and VLA-5 
receptors on cells adhering to matrix proteins, indirect im- 
munofluorescence studies were performed. A group of cells 
from the bladder carcinoma line EJ spread on Fn-coated cov- 
erslips (Fig. 9 a), and formed elaborate cell processes, which 
stained intensely for VLA-3. VLA-3 staining was distributed 
diffusely over the cell surface and not localized into cell con- 
tacts (Fig. 9 a). Interestingly, a few cells (Fig. 9 a, asterisk), 
or cell processes (arrow) within the same field (Fig.  9  b) 
were completely VLA-3 negative, thus indicating that VLA- 
3-positive staining was not an artifact. The surface distribu- 
tion of VLA-5 receptors on EJ ceils attached to Fn (Fig. 9 
c) was  clearly different from that of VLA-3.  Staining  for 
VLA-5 (Fig. 9 c) appeared to be intercellular (arrow), and 
occurred in some regions as bridgelike processes between 
cells (arrowhead). 
To examine putative differences between cell surface dis- 
tribution of VLA-3 on normal cells relative to transformed 
lines, immunofluorescence studies on the primary fibroblast 
cell line MRC-5 were also conducted. When MRC-5 fibro- 
blasts were plated on Fn and stained for VLA-5, many focal 
contacts were clearly observable (Fig.  9  d).  In contrast, 
diffuse staining of VLA-3, without localization to focal con- 
tacts, was seen for MRC-5 fibroblasts whether plated on Coil 
(Fig.  9  e),  or on Fn  (not  shown).  As  a  control,  MRC-5 
fibroblasts did form focal contacts on Coil as seen by staining 
of VLA B1 subunit (Fig. 9f). VLA-1 and VLA-2 receptors 
appeared to account for the localization of the/~  subunit 
into focal contacts (not shown).  In conclusion, the results 
above suggest that VLA-3 surface receptors are not involved 
in  the  formation  of  focal  adhesion  contacts  during  cell 
spreading on matrix proteins. 
•  VLA-3 and CeU-CeU Aggregation 
To determine if there was any involvement of VLA-3 in the 
homotypic aggregation of  NCI-H69 cells (the cells spontane- 
ously form large clumps), inhibition experiments were at- 
tempted. After NCI-H69 cell aggregates were disrupted by 
vigorous pipetting  or  by transient EDTA treatment,  anti- 
VLA-3, anti-VLA-6,  or anti-13~ mAbs were added and found 
The Journal of Cell Biology,  Volume 112, 1991  176 Figure 8. Affinity chromatography of LOX cells on columns of immobilized matrix proteins. Octylglucoside extracts of LOX cells were 
fractionated on either CoU type I-(A), or Lm-Sepharose (B) as described in Materials and Methods. 
not to inhibit reaggregation. Thus, although VLA-3 is likely 
to be a cell-cell adhesion receptor in other contexts (see In- 
troduction), we have found no evidence that VLA-3, or any 
other  VLA protein is  involved in the particular  cell-cell 
adhesion responsible  for homotypic NCI-H69 cell aggre- 
gation. 
Discussion 
Multiple Ligand Binding Functions for VLA-3 
We have used both biological and biochemical assays to es- 
tablish that VLA-3 can function as a receptor for Coll, Lm, 
and Fn. Previous studies had suggested that VLA-3 might 
bind these ligands (3, 18, 19, 57, 58), but the results were vari- 
able and a number of experiments failed to support this con- 
clusion (see Introduction and Table I). A key aspect of our 
study has been to use the small cell lung carcinoma line NCI- 
H69, which lacks the receptors VLA-1, VLA-2, VLA-4, and 
VLA-5,  to demonstrate VLA-3-mediated cell attachment. 
While VLA-3 on NCI-H69 cells mediated adhesion to Lm, 
Fn, and to a lesser extent to Coil, parallel experiments failed 
to show a similar role of VLA-3 on the melanoma cell line 
LOX. Instead, Coil binding was mediated by VLA-2, Lm by 
VLA-2 and VLA-6, and Fn by VLA-5.  Thus, the role of 
VLA-3 in the attachment of many adherent cell lines (such 
as  LOX  and  others  listed in  Table  I)  to  purified matrix 
ligands is not obvious because other integrins, with overlap- 
ping functions, may play more dominant roles. 
Affinity chromatography on immobilized Fn provided in- 
dependent confirmation of the  results  obtained with cell 
adhesion assays. When VLA-5 was first depleted from LOX 
cell extracts, or was absent to begin with (as in NCI-H69 
cells), nearly 100% of VLA-3 was observed to adhere to Fn. 
However, VLA-3 binding to Fn affinity columns in the pres- 
ence of VLA-5 was relatively weak. This result may explain 
why VLA-3  has  often not been  detected in previous  Fn 
affinity column experiments (4, 32, 42-44). 
VLA-3  binding  to  Fn-Sepharose  has  been  previously 
reported at low salt concentrations (57),  but was not seen 
with physiological buffers (32), thus suggesting that VLA-3 
binding requires low, nonphysiological salt levels. However, 
in this study we have shown that it is not physiological salt 
levels that prevent VLA-3 binding (e.g., in Fig. 6 B VLA-3 
bound quite well in the presence of 0.15 M NaC1), but rather 
the absence of VLA-5 seems to be the most critical factor 
(as mentioned above). 
At high ionic strength conditions (0.5 M NaC1),  VLA-3, 
but not VLA-5, was preferentially eluted from Fn columns. 
Also at high ionic strength conditions (0.5 M NaC1), VLA-3, 
but not VLA-2 could be selectively eluted from Coll and Lm 
affinity supports. Together these results suggest that VLA-3 
may have a lower avidity for its ligands compared to VLA-5 
binding to Fn, or VLA-2 binding to Coll or Lm. Alterna- 
tively, the salt-labile binding of VLA-3 to its ligands might 
indicate more of an electrostatic type of interaction. 
Interestingly, although VLA-6 is regarded as a Lm recep- 
tor of major functional importance (50, 51), it has not been 
Elices et al. Receptor Functions for the lntegrin  VLA-3  177 Figure 9. Immunofluorescent  localization  of VLA-3 compared to other integrins. (a) Bladder carcinoma (EJ) cells plated on Fn and stained 
for VLA-3 as described in Materials and Methods. (b) DIC image of the same field as in a; cells marked by arrowheads and by an asterisk 
are the same in both fields. (c) EJ cells plated on Fn and stained for VLA-5. The brought staining around the area of the nucleus is also 
observed with unrelated polyclonal antisera, and thus appears to be nonspecific. (d) MRC-5 fibroblast cells plated on Fn and stained for 
VLA-5. (e) MRC-5 fibroblasts plated on Coil and stained for VLA-3. ~) MCR-5 fibroblasts plated on Col1 and stained for the VLA fit 
subunit. 
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studies (11, 18, 38). Thus, in vitro biochemical assays alone 
may sometimes not reflect the functional contribution of an 
integrin within the context of an intact cell. 
Although the current  studies clearly establish multiple 
binding functions of VLA-3, we must also consider that the 
purified preparations of Coil, Lm, and Fn may not be the 
most physiologically relevant ligand(s) for VLA-3. For ex- 
ample, several other forms of Lm have recently been discov- 
ered,  including S-laminin  (30),  heart  laminin  (40),  and 
merosin (10). Also, there are many Coil types which have not 
been tested for VLA-3 binding. In addition, it was recently 
found that keratinocytes could secrete extracellular matrix 
mixtures that support both VLA-3-mediated attachment and 
localization to focal adhesions, better than any of  the purified 
VLA-3 ligands (3). Finally, although VLA-3 does not appear 
to have a role in NCI-H69 ceil-cell aggregation, emerging 
evidence from other  studies suggests a  potential role for 
VLA-3 in cell-cell adhesion (see Introduction). In this re- 
gard, it remains to be seen if VLA-3 might resemble another 
integrin, VLA-4, which has recently been shown to have 
both matrix and cellular ligands (12). 
VLA-3-mediated Binding Functions Are Both RGD 
Dependent and RGD Independent 
It appears that VLA-3 may recognize the RGD site in Fn be- 
cause (a)  RGD peptide caused specific elution of VLA-3 
(from two different ceil fines) from Fn and Fn-120 affinity 
columns, and (b) RGD peptide inhibited VLA-3-dependent 
binding to Fn in cell adhesion assays. These results clearly 
show that VLA-3 can interact with RGD-containing peptide, 
and they strongly suggest that VLA-3 is recognizing the RGD 
sequence in Fn. Also supporting VLA-3 binding to RGD in 
Fn,  we  found  that  VLA-3  directly  binds  to  the  RGD- 
containing 120-kD  Fn fragment, and we found that VLA-3 
binding to Fn was much more pronounced in the absence of 
VLA-5, another integrin that recognizes the RGD site. 
Because RGD peptide plus anti-VLA-3  mAb inhibited a 
little more effectively than either reagent alone, we cannot 
rule out that VLA-3 might recognize an additional "non- 
RGD" site in fibronectin, or that RGD peptide might also be 
inhibiting a small contribution from one or more other inte- 
grins which also binds to Fn in an RGD-dependent manner. 
In this regard, the integrins VLA-5, VNR, GPIIb/llIa (47), 
ot'#~ (1, 56), and u'#5 (6) also have the ability to recognize 
RGD  sites in theetr respective ligands, but,  as mentioned 
above, there is no evidence for expression of  these other inte- 
grins on NCI-H69 cells. 
In contrast to Fn, VLA-3 recognized other ligands in the 
RGD-independent manner. In experiments reported herein, 
the peptide GRGDSP did not inhibit or disrupt VLA-3 at- 
tachment to Coil, or to Lm in either cell adhesion, or affinity 
column assays. Consistent with our result, others have found 
that VLA-3 binds to mouse Lm at a site near the globular 
end of the long arm (19), in a region devoid of any RGD se- 
quences (48).  Other studies have also shown that RGD pep- 
tides did not inhibit adhesion of either purified VLA-3 (18) 
or whole cells (9) to Lm. Thus, among integrins known to 
interact with multiple ligands (21, 24, 36), VLA-3 appears to 
be unique in having both RGD-dependent and -independent 
ligands, implying that VLA-3 may have two functionally dis- 
tinct ligand binding sites. 
Differential Sensitivity of VLA-3 Adhesion Functions 
to Divalent Cations 
VLA-3 binding to different matrix ligands is differentially 
influenced by various divalent cations. For VLA-3-depen- 
dent adhesion to Fn, Mn  ++ caused a  pronounced stimula- 
tion, and Ca  ++ was markedly inhibitory relative to Mg++, 
whereas for Coil, the different cations gave essentially simi- 
lar results. Table II summarizes the essential data showing 
critical differences between VLA-3 ligands. Although the 
effect of divalent cations on VLA-3 binding to Lm was not 
determined, we would predict that Lm would resemble Coil, 
assuming that the two RGD-independent ligands would also 
share similar metal requirements. 
Several  other  integrin receptors  are  also  known to  be 
selectively influenced by the presence of various divalent 
metals. For example, binding of VLA-5 to an RGD peptide 
and to a Fn fragment has been shown to be strongly upregu- 
lated by Mn++ (17). In contrast, for other RGD-dependent 
integrins, including VNR and GPHb/IHa, the presence of 
Mn++ did not have a stimulatory effect, compared to Mg  ~ 
(17). Strong inhibitory effects with Ca++ have been reported 
in several RGD-independent interactions, such as VLA-2 
binding to Coil (52), and VLA-6 binding to Lm (50). 
While all known integrin functions are divalent cation de- 
pendent, there is little precedent for a single integrin having 
distinct ligand binding functions that are differentially regu- 
lated by divalent metals. The marked differences in cation 
sensitivity for VLA-3 binding to Fn, Coil, and/or Lm sug- 
gests that adhesion to separate ligands could be indepen- 
dently regulated in vivo, e.g., by localized changes in cal- 
cium levels.  A shift in divalent cation concentration would 
potentially effect VLA-3 quite differently than other VLA 
proteins, such as VLA-2, VLA-5, and VLA-6. For example, 
an increase in Ca  ++ levels, relative to Mg++, might be ex- 
pected to differentially downregulate the Coil and Lm bind- 
ing functions of VLA-2 and VLA-6, respectively, but not of 
VLA-3.  On  the other hand,  a  rise in Ca++ concentration 
would presumably cause dowm'egulation of Fn binding by 
VLA-3, but not by VLA-5. 
The positive correlation between RGD dependence and 
sensitivity to divalent metals (see Table II) strongly supports 
the concept of two functionally distinct ligand binding sites 
in VLA-3. Furthermore, a direct role is suggested for diva- 
lent cations, particularly Mn++, in supporting RGD binding 
by VLA-3.  A  model is envisioned whereby one particular 
divalent cation  site may participate  in the  interaction of 
VLA-3 with RGD,  perhaps with RGD directly involved in 
metal coordination (order of preference:  Mn++ >>  Mg  ++ 
>>  Ca++). In  contrast,  RGD-independent interactions of 
VLA-3, such as Coil (and maybe also Lm), may involve a 
Table I1. Summary of  Differences between VLA-3 
Recognition of  Fn, I_.m, and Collagen 
VLA-3  Inhibition by  Inhibition  Stimulation 
ligand  RGD peptide  by Ca  ++  by Mn  ++ 
CoU-I,IV  No  Low (15%)  Low (1.4-fold) 
Lm  No  ?  ? 
Fn  Yes  High (88%)  High (four-fold) 
Inhibition and stimulation  by divalent cations arc calculated relative to binding 
observed in the presenc  e of Mg  ++. 
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to the nature of the cation present. In this regard, human 
VLA-3 has at least three potential divalent cation sites in its 
ot  subunit,  as  revealed  by  sequence  analysis  of human 
(Takada,  Y., E. Murphy, P. Pil, C. Chert, M. H. Ginsberg, 
M. E. Hemler, manuscript submitted for publication) and 
hamster (55)  o~  3 eDNA. 
A Unique Role for VLA-3 Compared 
to Other Integrins  ? 
Despite the apparent overlap in functions between VLA-3 
and other integrins (VLA-1, VLA-2, VLA-5, and VLA-6), 
VLA-3  is  likely to  play  a  unique  role  in  cell adhesion 
phenomena. In addition to its broader ligand specificity, and 
its unusual ligand-dependent sensitivity to divalent cations, 
VLA-3 has lower apparent avidity for its ligands, and fails 
to rapidly localize into focal adhesions as compared to other 
integrins. Thus, for example, whereas increased VLA-5 ex- 
pression may contribute to more deposition of Fn matrix, 
and decreased cell migration (20), it is intriguing to specu- 
late that VLA-3 could mediate different, or perhaps even op- 
posite effects. Also consistent with a unique role for VLA-3, 
its level of expression often can be regulated differently than 
other integrins.  For example,  whereas  VLA-3  levels de- 
creased on quiescent fibroblasts,  VLA-1  was upregulated 
(I3). In similar fashion, TGF-/3 stimulation of MG-63 cells 
caused VLA-2 and VLA-5 to increase, while VLA-3 was 
down regulated (23).  In contrast, transformation of rodent 
fibroblasts caused a reduction in VLA-5 and other uniden- 
tiffed integrins, while VLA-3 levels were retained and per- 
haps even elevated (42).  Also, a chemically transformed os- 
teogenic sarcoma cell line had increased VLA-1, VLA-2, and 
VLA-6 levels, but not VLA-3 (8). 
In summary, this report indicates that VLA-3 adhesion 
functions are  remarkably versatile.  VLA-3  interacts with 
multiple matrix ligands by apparently both RGD-dependent 
and RGD-independent mechanisms. Furthermore, different 
VLA-3 binding activities show markedly disparate sensitivi- 
ties to the same panel of divalent cations. Together,  these 
findings support the notion that VLA-3 possesses function- 
ally distinct ligand binding sites. 
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